These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20856830)

  • 1. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
    Balint B; Watz H; Amos C; Owen R; Higgins M; Kramer B;
    Int J Chron Obstruct Pulmon Dis; 2010 Sep; 5():311-8. PubMed ID: 20856830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
    Cope S; Kraemer M; Zhang J; Capkun-Niggli G; Jansen JP
    Int J Chron Obstruct Pulmon Dis; 2012; 7():415-20. PubMed ID: 22848154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
    Cope S; Capkun-Niggli G; Gale R; Jardim JR; Jansen JP
    Int J Chron Obstruct Pulmon Dis; 2011; 6():329-44. PubMed ID: 21697997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
    Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
    Vogelmeier C; Ramos-Barbon D; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
    Respir Res; 2010 Oct; 11(1):135. PubMed ID: 20920365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J; Akitsu K
    Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
    Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
    Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
    Siler TM; LaForce CF; Kianifard F; Williams J; Spangenthal S
    Int J Chron Obstruct Pulmon Dis; 2014; 9():919-25. PubMed ID: 25214778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
    Rossi A; van der Molen T; del Olmo R; Papi A; Wehbe L; Quinn M; Lu C; Young D; Cameron R; Bucchioni E; Altman P
    Eur Respir J; 2014 Dec; 44(6):1548-56. PubMed ID: 25359348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
    Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
    Cope S; Zhang J; Williams J; Jansen JP
    BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.